Will the mRNA vaccine platform be the panacea for the development of vaccines against antimicrobial resistant (AMR) pathogens?

Click to increase image sizeClick to decrease image size

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

W. Chen: Conceptualization, Investigation, Writing - review & editing.

Additional information

Funding

The antimicrobial resistance research in our laboratories has been supported by NRC intramural (A-base) program under the Vaccine and Emerging Infection Research Initiative (Human Health and Therapeutics) and NRC Ideation Small Team Project (National Program Office). The view expressed here is solely the responsibility of the author and does not necessarily represent the official views of NRC.